PCP Prophylaxis At Higher CD4 Counts

2 April 1995

Members of the US Public Health Service Task Force have suggested that prophylaxis for Pneumocystis carinii pneumonia could be considered in HIV-infected patients with CD4 counts greater than 200/mm3. Current recommendations state that prophylaxis should begin when CD4 levels fall below 200/mm3. However, estimates from the US Centers for Disease Control say that 6% of patients have their first PCP episode when CD4 counts are between 200 and 300/mm3, translating to a prevention of 373 cases at current patient levels.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight